https://charts.traderzeitung.de/phases/US56400P7069
string(1408) "{"isin":"US56400P7069","name":"MannKind Corp","stock_id_xnas":7874361,"stock_id_xnys":null,"generated_at":"2026-07-08 17:10:00","days":[{"date":"2026-07-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":4.54,"close_at":"2026-07-06 15:25:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.35,"close_at":"2026-07-06 16:09:00","complete":true,"perf_pct":-4.185},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.21,"close_at":"2026-07-07 21:59:00","complete":true,"perf_pct":-3.2184},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-08","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.255,"close_at":"2026-07-08 17:08:00","complete":false,"perf_pct":1.0689},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
MannKind Aktie News & Nachrichten

MannKind Aktie News & Nachrichten

[WKN: A2DMZL | Symbol: MNKD]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
MannKind Chart

TOP-5-Kursziele der Analysten am 04.09.25

MannKind [US56400P7069] H.C. Wainwright bestätigt Buy-Rating und erhöht das Kursziel von 9 auf...

Darvas Screening: Marcus Corp., Interface, United Airlines, MannKind

Die NEO-DARVAS-STRATEGIE ist ein bemerkenswerter Trendfolgeansatz, der auf einem einfachen, aber wirkungsvollen...

MannKind Corporation: Mit Inhalationstechnologie auf Erfolgskurs

Erfolg mit Afrezza: Das inhalierbare Insulin Afrezza bietet Diabetikern eine praktische Alternative...

  • 1
MT Newswires 03.06.2026 13:05 Uhr

MannKind schließt Patientenrandomisierung in Phase-1b-Studie zur idiopathischen Lungenfibrose ab

07:04 AM EDT, 06/03/2026 (MT Newswires) -- MannKind (MNKD) teilte am Mittwoch mit, dass es die Patientenrandomisierung in seiner US-amerikanischen kli

MT Newswires 29.05.2026 18:52 Uhr

MannKind sagt, FDA genehmigt Afrezza für Kinder und Jugendliche mit Diabetes

12:51 PM EDT, 05/29/2026 (MT Newswires) -- MannKind (MNKD) teilte am Freitag mit, dass die US-amerikanische Food and Drug Administration Afrezza, sein